业务发展

Business development

全部分类

Product Pipeline

vvNew drugs (Class 1, Class 2.2)

Product Name	Indication	R & D Progress
		Preclinical	Clinical Trial Approval	Clinical Investigation	Listing Application	Approval
Vortioxetine Hydrobromide Orally Disintegrating Tablets	Depressive Disorder
FC027	TBD
FC013	Schizophrenia
FC010	Schizophrenia
FC017	Anxiety
FC026	Peripheral neuralgia

Imported Generic Drugs

项目代号	适应症	China Declaration Progress				Approved Regions
		Pharmaceutical Research	Clinical Tests	Listing Application	Approval
Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation	Routine treatment of reversible obstructive airway diseases, including asthma in adults and children, administered as a combination therapy					USA, Europe
Brexpiprazole Tablets	Schizophrenia					USA
Sirolimus Tablets	Prevention of organ rejection in patients aged ≥13 years undergoing renal transplantation					USA
Dydrogesterone Tablets	Diseases caused by progesterone deficiency					India
FC028	Treatment of iron deficiency in adults					India
FC029	Diabetes mellitus					****
FC030	Cancers					USA
FC031	COPD					USA

MAH-backed Generic Drugs

Product Name	Indication	Declaration Progress
		Pharmaceutical Research	Clinical Tests	Listing Application	Approval
Trazodone Hydrochloride Tablets	Depressive Disorder
Trazodone Hydrochloride Sustained-Release Tablets	Depressive Disorder
Perospirone Hydrochloride Tablets	Schizophrenia

Room 1502-1506, Building D2, Nanshan iPark, No. 1001, Xueyuan Avenue, Changyuan Community, Taoyuan Street, Nanshan District, Shenzhen, China.